PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $35.2 million in its first quarter.

The Palo Alto, California-based company said it had a loss of 20 cents per share. Losses, adjusted to extinguish debt, were 5 cents per share.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 40 cents per share.

The rare disease drug developer posted revenue of $211.1 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $140.1 million.

BridgeBio Pharma shares have fallen 33% since the beginning of the year. The stock has climbed 88% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO